AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

Shernan G. Holtan; Luis F. Porrata; Ivana N M Micallef; Douglas J. Padley; David J. Inwards; Stephen A. Ansell; Patrick B. Johnston; Dennis A. Gastineau; Svetomir N. Markovic

doi:10.3816/CLM.2007.n.009

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

Shernan G. Holtan, Luis F. Porrata, Ivana N M Micallef, Douglas J. Padley, David J. Inwards, Stephen A. Ansell, Patrick B. Johnston, Dennis A. Gastineau, Svetomir N. Markovic

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34⁺ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 10⁹ lymphocytes/kg vs. 0.288 × 10⁹ lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

Original language	English (US)
Pages (from-to)	315-318
Number of pages	4
Journal	Clinical Lymphoma and Myeloma
Volume	7
Issue number	4
DOIs	https://doi.org/10.3816/CLM.2007.n.009
State	Published - Jan 2007

Keywords

Autograft absolute lymphocyte count
Endpoint
Granulocyte colony-stimulating factor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3816/CLM.2007.n.009

OpenUrl availability

Full text

Cite this

Holtan, S. G., Porrata, L. F., Micallef, I. N. M., Padley, D. J., Inwards, D. J., Ansell, S. A., Johnston, P. B., Gastineau, D. A., & Markovic, S. N. (2007). AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma. Clinical Lymphoma and Myeloma, 7(4), 315-318. https://doi.org/10.3816/CLM.2007.n.009

@article{dba46eafa15e4a7a9fde281fb7476133,

title = "AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma",

abstract = "Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.",

keywords = "Autograft absolute lymphocyte count, Endpoint, Granulocyte colony-stimulating factor",

author = "Holtan, {Shernan G.} and Porrata, {Luis F.} and Micallef, {Ivana N M} and Padley, {Douglas J.} and Inwards, {David J.} and Ansell, {Stephen A.} and Johnston, {Patrick B.} and Gastineau, {Dennis A.} and Markovic, {Svetomir N.}",

year = "2007",

month = jan,

doi = "10.3816/CLM.2007.n.009",

language = "English (US)",

volume = "7",

pages = "315--318",

journal = "Clinical Lymphoma and Myeloma",

issn = "1557-9190",

publisher = "Cancer Media Group",

number = "4",

}

TY - JOUR

T1 - AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

AU - Holtan, Shernan G.

AU - Porrata, Luis F.

AU - Micallef, Ivana N M

AU - Padley, Douglas J.

AU - Inwards, David J.

AU - Ansell, Stephen A.

AU - Johnston, Patrick B.

AU - Gastineau, Dennis A.

AU - Markovic, Svetomir N.

PY - 2007/1

Y1 - 2007/1

N2 - Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

AB - Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

KW - Autograft absolute lymphocyte count

KW - Endpoint

KW - Granulocyte colony-stimulating factor

UR - http://www.scopus.com/inward/record.url?scp=33947184359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947184359&partnerID=8YFLogxK

U2 - 10.3816/CLM.2007.n.009

DO - 10.3816/CLM.2007.n.009

M3 - Article

C2 - 17324341

AN - SCOPUS:33947184359

SN - 1557-9190

VL - 7

SP - 315

EP - 318

JO - Clinical Lymphoma and Myeloma

JF - Clinical Lymphoma and Myeloma

IS - 4

ER -

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this